Interval or Late Debulking Surgery in Advanced Ovarian Cancer: Progression Free and Overall Survival Advantages

Size: px
Start display at page:

Download "Interval or Late Debulking Surgery in Advanced Ovarian Cancer: Progression Free and Overall Survival Advantages"

Transcription

1 Med. J. Cairo Univ., Vol. 83, No. 2, March: 63-68, Interval or Late Debulking Surgery in Advanced Ovarian Cancer: Progression Free and Overall Survival Advantages LOAIE EL-HELW, M.D. 1, 2 and HANAA EL-KHENINI, Ph.D. 3, 4 The Department of Medical Oncology, Mansoura University, Egypt 1 & the City General Hospital, University Hospitals of North Staffordshire, Stoke-On-Trent, UK 2 and the Departments of Public Health, Mansoura University, Egypt 3 & E-Health, the University of Manchester, UK 4 Abstract Purpose: Interval (IDS) or late debulking surgery (LDS) following neoadjuvant chemotherapy (NAC) may have a role in treating advanced epithelial ovarian cancer (AEOC) where primary debulking surgery is not possible. We aimed to study the outcome of such patients who were treated in our centre during the last 3 years. Methods: This was retrospective study of AEOC patients who had NAC with or without IDS/LDS in the City General Hospital, Stoke-On-Trent between May 2011 and July Results: Forty six patients with AEOC were treated under our oncology team during that period. Thirty one patients (67.4%) were in stages III and 15 were in stage IV (32.6%). All patients were recommended NAC; 30 patients (65.2%) had paclitaxel and carboplatin regimen and 16 (34.8%) single agent carboplatin. Response to chemotherapy was assessed after 2 cycles. Twenty seven patients (58.7%) had partial response, 16 (34.8%) stable disease and 3 (6.5%) progressive disease. Seventeen patients (37%) proceeded to IDS after cycle 3 and 4 patients (8.7%) to LDS after cycle 6. After a median follow-up period of 12 months, 39 patients (84.8%) had relapsing/progressive disease. The median progression free survival duration (PFS) for all patients was 9 months and 2 years PFS probability was 4.5%. The median PFS was 10 months for patients who had either IDS or LDS compared to 8 months for no debulking. The median overall survival (OS) duration was not reached yet but the 2 years OS probability was 76% for all patients; 94% for patients who had IDS and 58% for no debulking. One year OS probability for patients who had late debulking was 100%. Conclusion: In our study, we documented PFS and OS advantages for patients who IDS or LDS and therefore should be considered whenever possible as part of the primary treatment of AEOC patients. Key Words: Advanced ovarian cancer Neoadjuvant chemotherapy Debulking surgery. Correspondence to: Dr. Loaie M. El-Helw, loaieelhelw@hotmail.com, loaie.elhelw@uhns.nhs.uk Introduction APPROXIMATELY 70% to 80% of the ovarian cancer patients are in stage III or IV when first diagnosed. The current standard treatment for epithelial ovarian cancer (EOC) consists of primary debulking surgery (PDS) followed by paclitaxel and platinum chemotherapy. Optimal cytoreduction-in those patients-to no macroscopic residual disease is difficult to achieve with reported rate of less than 25% despite maximal efforts [1]. Also, most patients diagnosed with advanced epithelial ovarian cancer (AEOC) are elderly, with multiple comorbidities, and poor performance status. Therefore aggressive surgery is significantly limited in these patients. Neoadjuvant chemotherapy (NAC) is associated with 70-80% response rate in AEOC and can result in adequate tumour shrinkage. Therefore, NAC followed by interval debulking surgery (IDS) has been considered as an alternative to conventional PDS in treating AEOC [2,3]. The timing of IDS is usually after 2-4 cycles of chemotherapy. The value of late debulking surgery (LDS) after 6 cycles is not clear as there is a chance of emergence of more chemotherapy resistant tumour clones. Therefore, in our study we reviewed the management of our patients who presented with AEOC and were not candidate for PDS. We studied their outcome in relation to timing of debulking surgeries. Patients and Methods Retrospective study of patients with advanced ovarian cancer who had NAC with or without IDS/LDS treated in our centre in the City General Hospital, the University Hospital of North Staffordshire since May 2011 till July Electronic patients and gynaecology multidisciplinary (GM- 63

2 64 Interval or Late Debulking Surgery in Advanced Ovarian Cancer DT) meetings records were reviewed. Data analysis was performed using SPSS statistical package version 16. Overall survival (OS) and progressionfree survival (PFS) probabilities were analysed using the Kaplan-Meier method. The log-rank test and Cox-regression multivariate analysis were used to investigate the differences in survival between the study groups. p<5 was considered statistically significant. Results Demographic data: Table (1) describes the demographic features of the patient in the study. Forty six patients with AEOC who were not candidate for PDS were included. The median age was 71 years old (range 37-86). Thirty one patients presented in clinical stage (CS) III (67.4%) and 15 (32.6%) CS IV. Serous papillary adenocarcinoma was the most common histologic subtype (91.3%). Four patients (8.7%) presented with primary peritoneal carcinomatosis (PPC) but the majority had advanced ovarian cancer presenting with adnexal masses and wide spread diseases. Table (1): Demographic data of the 46 studied patients. Variables Number Percent Clinical stage: III IV Grade: Grade Grade Missing data 10 Histology: Serous Clear cells Mucinous Undetermined subtypes Clinical subtypes: EOC PPC GMDT plan: NAC/IDS Palliative chemotherapy NAC: Paclitaxel and carboplatin Carboplatin EOC : Epithelial ovarian cancer. PPC : Primary peritoneal carcinoma. NAC : Neoadjuvant chemotherapy. IDS : Interval debulking surgery. All our patients were discussed in the GMDT meetings on initial presentations where their management plans were decided. Forty two (91.3%) patients were decided to have NAC/IDS and 4 patients (8.7%) were to have palliative chemotherapy only due to poor performance status (PS) although all patients were reviewed once again after 2 cycles of chemotherapy for possibility of IDS. Paclitaxel and carboplatin regimen was the most commonly used NAC (65.2%) and single agent carboplatin was used in the rest of patients (34.8%). Response and outcome: Response to chemotherapy was assessed after 2 cycles of chemotherapy and patients were rediscussed in the GMDT meetings. Twenty seven patients (58.7%) had partial response (PR) to chemotherapy, 16 (34.8%) stable disease (SD) and 3 (6.5%) progressive disease (PD). Only 17 patients (37%) were recommended to proceed to IDS. Further 18 (39.1 %) were not suitable for IDS but were recommended to continue chemotherapy with further review following cycle 5; only 4 (8.7%) of them proceeded to LDS. Overall 21 patients (45.7%) had IDS/LDS. More patients with clinical stage III proceeded to have debulking surgery than CS IV; nearly 48% of patients with CS III had IDS and 6.5% had LDS. For patients with CS IV, 13.3% had IDS and 13.3% LDS. Complete surgical cytoreduction was achieved in 16 patients (34.8%) but 5 patients (1%) had suboptimal debulking with residual macroscopic disease. Maximal cytoreduction was achieved in all of the 4 patients (100%) who had LDS and in 12 of the 17 who had IDS (7%) (Table 2). After a median follow-up period of 12 months (range 5-40), 39 patients (84.8%) had relapsing/ progressive disease and had a median of 2 (range 1-4) further lines of systemic anticancer treatment (SACT). All patients who had IDS and 1 out 4 patients (25%) who had LDS, have eventually relapsed and 21 of 25 patients (84%) who did not have any debulking surgery had PD. Only 2 patients (4.4%) had single area of relapse and underwent further surgical resection followed by chemotherapy. Fifteen patients (83.3%) with IDS/LDS had platinum free interval (PFI) of >_6 months compared to only 47.6% for patients with no debulking surgery (p-19 Pearson Chi-Square) (Table 3). Survival data: The median progression free survival duration (PFS) for all patients was 9 months (range 8-10 months) and 2 years PFS probability was 4.5% Fig. (1). The median PFS was 10 months (range 8-11) for patients who had IDS or LDS compared to 8 months (range 6-9) for no debulking (p-5) Fig. (2). The median PFS durations were 11, 10 and 8 months for patients who had complete, in-

3 Loaie El-Helw & Hanaa El-Khenini 65 complete cytoreduction or no debulking respectively (p-3) although the difference in median PFS for complete and incomplete cytoreduction was statistically insignificant (p-01) Fig. (3). The median PFS for patients who had debulking (IDS/ LDS) compared to no debulking were (10 and 8 months; p-15). None was statistically significant in Cox-regression analysis. Over the follow-up period, 1 patient of 17 (5.9%) patients who had IDS and 7 of the 25 who had no debulking (28%) have died. All patients with LDS are still alive. Table (2): Response and outcome. Variables Number Percent Response after 2 cycles: PR SD PD GMDT decisions after 2 cycles: Proceed to IDS Review after 5 th cycle No debulking Number of cycles to debulking: 3 Cycles (IDS) cycles (LDS) No debulking Debulking in relation to stage: Clinical stage III (31 patients): IDS (after 3 cycles NAC) LDS (after 6 cycles NAC) No debulking Clinical stage IV (15 patients): IDS (after 3 cycles NAC) LDS (after 6 cycles NAC) No debulking Surgical Cytoreduction: Complete Incomplete (residual disease) 5 1 No debulking Debulking in relation to cytoreduction: IDS (17 patients): Complete 12 7 Incomplete LDS (4 patients): Complete Incomplete 0 0 NAC : Neoadjuvant chemotherapy. IDS : Interval debulking surgery (after 3 cycles). PR : Partial response. SD : Stable disease. PD : Progressive disease. LDS : Late debulking surgery (after 6 cycles). The median overall survival (OS) data were not reached yet but the 2 years OS probability was 76% Fig. (4). The 2-years survival probability was 94% for patients who had IDS after 3 cycles compared to 58% for no debulking (p-9 Log Rank). One year OS probability for patients who had late debulking was 100% Fig. (5). The relation of OS to degree of cytoreduction is shown in Fig. (6) where 2 years OS probability was 94% for complete cytoreduction compared to 58% for no debulking (p-9). All patients with suboptimal debulking are still surviving at 1.5 years of follow-up. Patients who had platinum free interval (PFI) of > 12 months have the highest survival probability compared to PFI of 6-12 months and <6 months (p.008) Fig. (7). In Cox-regression multivariate analysis, none of these variables was statistically significant. Table (3): Relapse data among the studied patients. Variables Number Percent Relapse/progression: Yes No Relapse in relation to IDS/LDS: IDS & relapse (17 patients): Yes No 0 0 LDS & relapse (4 patients): Yes 1 25 No 3 75 No debulking (25 patients): Yes No 4 16 Pattern of relapse: Isolated site Multiple areas Further debulking surgery at relapse: Yes No Platinum free interval: IDS/LDS (18 relapsed patients): <6 months/refractory months 9 50 >12 months No debulking (21 relapsed patients): <6 months/refractory months >12 months IDS : Interval debulking surgery. LDS : late debulking surgery. SACT : Systemic anticancer treatment.

4 66 Interval or Late Debulking Surgery in Advanced Ovarian Cancer N cycles to Debulking 3 cycles (IDS) 6 cycles (LDS) Fig. (1): Primary progression free survival for all studied patients Fig. (2): Primary progression free survival in relation to timing of Debulking surgery. Surgical cytoreduction Complete Incomplete (residual disease) Fig. (3): Primary progression free survival in relation to degree of cytoreduction. Fig. (4): Overall survival in the studied patients. N cycles to Debulking 3 cycles (IDS) 6 cycles (LDS) Surgical cytoreduction Complete Incomplete (residual disease) Fig. (5): Overall survival in relation to timing of Debulking surgery. Fig. (6): Overall survival in relation to degree of cytoreduction.

5 Loaie El-Helw & Hanaa El-Khenini 67 Platinum free interval >12 months 6-12 months <6 months Fig. (7): Overall survival in relation to platinum free inteeval. Overall, higher PFS was achieved for patients who had IDS/LDS compared to no debulking (10 and 8 months respectively). The median survival duration for the studied patients has not been reached yet. All patients with LDS are still surviving at 1 year (100% OS) as well as 94% of patients who had IDS. Of note that the 4 patients who had LDS were diagnosed in 2013 and early 2014, therefore their follow-up period is still short (median 10 months; range 9-12). The 1 and 2 years OS for the no debulking patients group was 58%. These findings emphasize the importance of debulking surgeries whether IDS or LDS as they are associated with better PFS and OS compared with no debulking. Discussion Neoadjuvant chemotherapy and interval debulking surgery (NAC/IDS) is an acceptable safe approach to achieve optimal cytoreduction in patients with advanced epithelial ovarian cancer who are not candidate for primary debulking surgery [4-6]. The best timing to perform cytoreductive surgery after NAC is still unclear. In a meta-analysis by Bristow and Chi, it was found that increasing the number of chemotherapy cycles prior to the debulking surgery had a negative survival effect. Thus, a definitive operative intervention should be undertaken early in the treatment program as possible [7]. That concept was also reported by Colombo and colleagues who found that patients with AEOC receiving complete IDS after more than 4 cycles of NAC have poor prognosis [8]. However, another meta-analysis did not show that increasing the number of NAC cycles adversely affected OS [3]. In our study, 46 patients with stage III and IV AEOC were not candidate for primary debulking surgery (PDS) and therefore were offered NAC and consideration of IDS. All patients were rediscussed in our GMDT meetings after 2 cycles of NAC and accordingly 17 patients (37%) had adequate response and proceeded to IDS after 3 NAC cycles. Eleven patients (23.9%) were not candidateat all-for debulking surgery for wide spread disease distribution and/or inadequate response to NAC. The rest of our patients (18; 39.1%) showed slow response to NAC based on radiological or laparoscopic assessment and therefore complete cytoreduction was considered non-achievable at that stage. They have been further reassessed following cycle 5 of NAC and only 4 were selected for LDS. The definition of 'optimal cytoreduction' has moved from its former meaning of a cytoreduction to 1cm of residual disease to no residual disease [9,10]. Tumour resection with >1cm of residual disease (15-30% of patients) places these patients at risk of morbidities of the cytoreductive attempt without survival benefit [11]. In agreement with that, our patients who had optimal debulking surgeries, had significantly longer median PFS compared to patients who had suboptimal debulking surgeries or no debulking at all (11, 10 and 8 months respectively). Patients, who had IDS/LDS, had higher chance of having platinum sensitive disease when they relapsed with platinum free interval (PFI) of more than 6 months. Also, 1.5 years OS probabilities were higher for our patients who had optimal and suboptimal debulking surgeries compared to patients who had no debulking. Patients with PFI of more than 6 months had higher OS compared to patients with platinum resistant ovarian cancer. On conclusion, IDS and LDS offer better PFS and OS for patients with AEOC who are not candidate for PDS. Debulking surgeries in patients with AEOC increase the percentage of patients who have platinum free interval of >_6 months and therefore have more chances to respond to further platinum regimens. References 1- GALLO A. and FRIGERIO L.: Neoadjuvant chemotherapy and surgical considerations in ovarian cancer. Curr. Opin. Obstet. Gynecol., 15 (1): 25-31, MORICE P., DUBERNARD G., REY A., et al.: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J. Am. Coll. Surg., 197 (6): , 2003.

6 68 Interval or Late Debulking Surgery in Advanced Ovarian Cancer 3- KANG S. and NAM B.H.: Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann. Surg. Oncol., 16 (8): , ZHENG H. and GAO Y.: Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Chin., J. Cancer Res., 24 (4): 304-9, KEYVER-P., ZIVANOVIC O. and RUDLOWSKI C.: Interval debulking surgery in patients with Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV ovarian cancer. Onkologie., 36 (6): , MARKAUSKAS A., MOGENSEN O., DEPONT CHRIS- TENSEN R., et al.: Primary surgery or interval debulking for advanced epithelial ovarian cancer: Does it matter. Int. J. Gynecol. Cancer., 24 (8): , BRISTOW R.E. and CHI D.S.: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol. Oncol., 103 (3): , COLOMBO P.E., LABAKI M., FABBRO M., et al.: Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer Gynecol. Oncol., S (14) , THIGPEN T., DUBOIS A., MCALPINE J., et al.: Firstline therapy in ovarian cancer trials. Int. J. Gynecol. Cancer, 21 (4): , VERGOTE I., TROPÉ C. and AMANT F.: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med., 363 (10): , CHANG S. and BRISTOW R.: Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining 'optimal' residual disease. Gynecol. Oncol., 125 (2): , 2012.

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

COMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER

COMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards

More information

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer REVIEW ARTICLE 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference Gavin C.E. Stuart, MD, FRCSC,*

More information

First-line chemotherapy for the treatment of women with epithelial ovarian cancer

First-line chemotherapy for the treatment of women with epithelial ovarian cancer First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer June 2014

More information

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum

More information

Original Article. Clinical Trials (KKS), University Marburg (AGO-OVAR statistical centre), Germany;

Original Article. Clinical Trials (KKS), University Marburg (AGO-OVAR statistical centre), Germany; Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer. Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK

Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer. Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK Overview of Presentation This presentation will discuss the management

More information

Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure

Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

Management of Platinum-Sensitive Recurrent Ovarian Cancer

Management of Platinum-Sensitive Recurrent Ovarian Cancer Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.

More information

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths

More information

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012 Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically

More information

Optimal treatment of early-stage ovarian cancer

Optimal treatment of early-stage ovarian cancer Annals of Oncology Advance Access published March 14, 2014 1 Optimal treatment of early-stage ovarian cancer F. Collinson *,1, W. Qian *,2, R. Fossati 3, A. Lissoni 4, C. Williams 5, M. Parmar 6, J. Ledermann

More information

First-line chemotherapy for women with epithelial ovarian cancer

First-line chemotherapy for women with epithelial ovarian cancer First-line chemotherapy for women with epithelial ovarian cancer A systematic review July 2013 First line chemotherapy for women with epithelial ovarian cancer: a systematic review was prepared and produced

More information

Ovarian cancer. A guide for journalists on ovarian cancer and its treatment

Ovarian cancer. A guide for journalists on ovarian cancer and its treatment Ovarian cancer A guide for journalists on ovarian cancer and its treatment Contents Contents 2 3 Section 1: Ovarian Cancer 4 i. Types of ovarian cancer 4 ii. Causes and risk factors 5 iii. Symptoms and

More information

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE

SYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1

More information

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) MEDICAL POLICY INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: CS141.A Effective Date: September 1, 2015 Table of Contents COVERAGE RATIONALE DEFINITIONS... APPLICABLE CODES..

More information

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006

The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy

More information

CA 125 definitions agreed by GCIG November 2005

CA 125 definitions agreed by GCIG November 2005 CA 125 definitions agreed by GCIG November 2005 The GCIG has agreed criteria for defining response and progression of ovarian carcinoma which use the serum marker CA 125, and the situations where these

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D. Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

Ching-Yao Yang, Yu-Wen Tien

Ching-Yao Yang, Yu-Wen Tien Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

EPITHELIAL OVARIAN CANCER

EPITHELIAL OVARIAN CANCER EPITHELIAL OVARIAN CANCER Executive Summary Epithelial ovarian cancer is the most common type of ovarian cancer and the most aggressive gynecological malignancy. Approximately 70% of patients are diagnosed

More information

REVIEW ARTICLE. Key Words: CA 125, Ovarian cancer, Response, Progression, RECIST, Clinical trials

REVIEW ARTICLE. Key Words: CA 125, Ovarian cancer, Response, Progression, RECIST, Clinical trials REVIEW ARTICLE Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Gordon John Sampson Rustin,

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2016 3/2017

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Gynecologic Oncology

Gynecologic Oncology Gynecologic Oncology 123 (2011) 456 460 Contents lists available at SciVerse ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Therapy-related myeloid leukemia after treatment

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Please see the LUCADA data manual v3.1.3, available in the downloads section

Please see the LUCADA data manual v3.1.3, available in the downloads section National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands

More information

Endometrial Cancer. Measurability of Quality Performance Indicators Version 2.0

Endometrial Cancer. Measurability of Quality Performance Indicators Version 2.0 Endometrial Cancer Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Endometrial Cancer QPIs Final Publication v2 Endometrial QPI Dataset (latest published version)

More information

Abstract. Objectives. Methods. Results. a11111

Abstract. Objectives. Methods. Results. a11111 RESEARCH ARTICLE Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients Shuang Ye 1, Jiaxin Yang 1, Yan

More information

with ovarian cancer exhibit an initial response. 5 In addition, the majority of

with ovarian cancer exhibit an initial response. 5 In addition, the majority of Research ONCOLOGY Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer Laura J. Havrilesky, MD, MHSc; Thomas C. Krivak, MD; John W. Mucenski, PharmD; Evan R. Myers, MD, MPH OBJECTIVE:

More information

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone

More information

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center

More information

Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence

Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence Journal of BUON 17: 735-739, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Review)

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Review) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Review) Jaaback K, Johnson N, Lawrie TA This is a reprint of a Cochrane review, prepared and maintained by

More information

Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy

Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy ORIGINAL ARTICLES 613 Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy S K Tay,*FAMS, MD, FRCOG, L K Tan,**MBBS, M Med (O & G), MRCOG Abstract

More information

Kidney Cancer OVERVIEW

Kidney Cancer OVERVIEW Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney

More information

Gynäkologische Onkologie-Klinische Studien

Gynäkologische Onkologie-Klinische Studien Gynäkologische Onkologie-Klinische Studien Breast cancer A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Chirurgia Avanzata Del Carcinoma Ovarico Nuove Strategie A Confronto Ovarian Cancer Advanced Surgery New Strategies in Comparison

Chirurgia Avanzata Del Carcinoma Ovarico Nuove Strategie A Confronto Ovarian Cancer Advanced Surgery New Strategies in Comparison Peritoneal dissection and intraperitoneal chemotherapy under hyperthermic conditions. If you select the right patients long-term survival can be achieved. Chirurgia Avanzata Del Carcinoma Ovarico Nuove

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Surgical Staging of Endometrial Cancer

Surgical Staging of Endometrial Cancer Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging

More information

EOC - A Case Study in Conservative Fertility Sparing Surgical Treatment of Invasive Epithelial Cancer

EOC - A Case Study in Conservative Fertility Sparing Surgical Treatment of Invasive Epithelial Cancer is Conservative Fertility-Sparing Surgical Treatment of Invasive Epithelial Ovarian Cancer: When Is It Acceptable? Joseph Menczer MD Gynecologic Oncology Unit, Department of Obstetrics and Gynecology,

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental

Mesothelioma. Information for Patients and Families. identifying and evaluating experimental Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical

More information

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with

More information

The Kaplan-Meier Plot. Olaf M. Glück

The Kaplan-Meier Plot. Olaf M. Glück The Kaplan-Meier Plot 1 Introduction 2 The Kaplan-Meier-Estimator (product limit estimator) 3 The Kaplan-Meier Curve 4 From planning to the Kaplan-Meier Curve. An Example 5 Sources & References 1 Introduction

More information

Management of low grade glioma s: update on recent trials

Management of low grade glioma s: update on recent trials Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,

More information

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

Epithelial Ovarian Cancer:

Epithelial Ovarian Cancer: Women s Health Care Epithelial Ovarian Cancer: Not So Asymptomatic It is imperative to correlate the potential symptoms of ovarian cancer and make a prompt diagnosis of this often aggressive disease. By

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

How To Compare The Effects Of A Hysterectomy And A Hysterectomy

How To Compare The Effects Of A Hysterectomy And A Hysterectomy A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER

ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER AFA 08958 From Bench to Bedside From KK DT1 10/27/2015 12:04 PM 01 ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER Hak Choy, MD University of Texas Southwestern Medical Center Dallas, Texas, USA Orchestrating

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Understanding Clinical Trials

Understanding Clinical Trials Understanding Clinical Trials HR =.6 (CI :.51.7) p

More information

Latest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea

Latest developments in management. Gianfilippo Bertelli Consultant Medical Oncologist Swansea Latest developments in management Gianfilippo Bertelli Consultant Medical Oncologist Swansea Optimizing management of ovarian cancer in South Wales Diagnosis and referral pathways: Role of GPs, gynaecologists,

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed

More information

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center

What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.

More information

Comments: Policy Accepted during 2013 Annual Review with no changes.

Comments: Policy Accepted during 2013 Annual Review with no changes. Health Plan Coverage Policy ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 09/18/2013 Title: Cytoreduction Surgery with Hyperthermic Intraperitoneal Chemotherapy Comments: Policy

More information

The role of PARP inhibitors in high grade serous ovarian cancers

The role of PARP inhibitors in high grade serous ovarian cancers The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair

More information

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University

More information

Endpoints and quality of life

Endpoints and quality of life Endpoints and quality of life PFS, OS, quality of life and medico-economic assessment in oncology Isabelle Durand-Zaleski, Jérôme Garnier, Mira Pavlovic, and participants of roundtable n 3 Pascal Bilbault,

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

Luis D. Carcorze Soto, MD PGY-3

Luis D. Carcorze Soto, MD PGY-3 Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:

More information

Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter

Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter Susan C. Modesitt, MD, Edward J. Pavlik, PhD, Frederick R. Ueland, MD, Paul D. DePriest, MD, R. J. Kryscio, PhD,

More information

Progress and Prospects in Ovarian Cancer Screening and Prevention

Progress and Prospects in Ovarian Cancer Screening and Prevention Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian

More information

Endometrial Cancer Treatment

Endometrial Cancer Treatment Endometrial Cancer Treatment January 2006 By Shelly Smits, RHIT, CCS, CTR mary by Ian Thompson, MD Data Source: Cancer registry information on uterine cancer diagnosed 1/1/2000 to 12/31/2004. Reason for

More information

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS Description of Treatment A major difficulty in treating

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

National Medical Policy

National Medical Policy National Medical Policy Subject: Policy Number: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers NMP346 Effective Date*: June 2007 Updated: November 2014 This National Medical Policy

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer

Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Camran Nezhat,, MD, FACOG, FACS Stanford University Medical Center Center for Special Minimally Invasive

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information